MedTrace Logo

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

NCT01715012 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-05-15

No results posted yet for this study

Summary

This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether treatment with ST266 results in less scarring, in subjects with diabetes separately comparing healing of the skin graft and the skin graft donor site using ST266 plus a burn dressing versus placebo and a burn dressing.

Conditions

Interventions

BIOLOGICAL

ST266

ST266 is applied daily by spray to burn wound and skin graft donor site

DRUG

Saline

Saline is applied daily by spray to burn wound and skin graft donor site

Sponsors & Collaborators

  • Noveome Biotherapeutics, formerly Stemnion

    lead INDUSTRY

Principal Investigators

  • Larry Jones, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-01-31
Completion
2015-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715012 on ClinicalTrials.gov